A. Vindevoghel

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Henri Roché, P. Fumoleau, M. Spielmann et al. · Journal of Clinical Oncology · 2006 · 572 citations · Full text

Medicine, Oncology, Pharmacology +16

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 501 citations

Medicine, Oncology, Breast Oncology +13

Multifactorial Approach to Predicting Resistance to Anthracyclines

Christine Desmedt, Angelo Di Leo, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2011 · 187 citations

Medicine, Oncology, Pharmacology +16

Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer

Martine Piccart, Angelo Di Leo, M. Beauduin et al. · Journal of Clinical Oncology · 2001 · 163 citations

Medicine, Oncology, Pharmacotherapy +11

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

Angelo Di Leo, Denis Larsimont, David Gancberg et al. · Annals of Oncology · 2001 · 107 citations

Medicine, Oncology, Pharmacology +17